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Clinical Trial
Oral Rapamycin Reduces In-Stent Restenosis
Although drugs eluted from stents reduce in-stent restenosis (ISR), an oral agentwould allow use of the optimal stent without regard to the attached drug, and
therapy could be tailored to the patient’s chance of ISR. The Oral Rapamycin in
Argentina (ORAR II) study randomized 100 patients with de novo lesions being
treated with bare-metal stents to either two weeks of oral rapamycin or no therapy.
Follow-up angiography at nine months showed that rapamycin reduced the binary ISR
rate by 65%. The drug was fairly well tolerated, with 26% of subjects reporting a
probable side effect, but only 4% stopping therapy early. This study shows that short
term systemic rapamycin can reduce ISR. See page 1522. See figure.
Coronary Artery Disease
Meta-Analysis Shows That ACEIs Modestly Reduce CV Risk
Angiotensin-converting enzyme inhibitors (ACEIs) affect multiple metabolic path-ways that theoretically should reduce atherosclerotic events, yet the clinical trial
evidence of this benefit has been conflicting. Al-Mallah and colleagues performed a
systematic meta-analysis of the benefits of ACEIs in patients with either documented
coronary artery disease (CAD) or at high risk for CAD but no history of systolic
dysfunction. This analysis, which incorporates over 30,000 subjects and five different
ACEIs, shows a consistent, albeit modest, reduction in cardiovascular end points.
Although the relative risks were reduced by 10% to 20%, the absolute risk reductions
were small. The authors calculate that 100 patients would have to be treated for more
than four years with an ACEI in order to prevent one death. See page 1576.
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Hyperlipidemia and
Metabolic Syndrome
Metabolic Syndrome Increases Cardiac Risk in the Elderly
The metabolic syndrome (MetSyn) is defined as three of the following five criteria:increased waist circumference, triglycerides 150 mg/dl, low high-density li-
poprotein cholesterol, elevated blood pressure, and fasting glucose 110 mg/dl.
Although this syndrome is known to be associated with increased cardiovascular risk in
the general population, it is not clear if it imposes the same risk in elderly populations
(70 years). Butler and colleagues studied the impact of the MetSyn on the more than
3,000 elderly subjects enrolled in the Health ABC Study. Both myocardial infarction
and hospitalizations for heart failure were significantly more common in subjects who
met the criteria for the MetSyn with a hazard ratio of 1.5. This study confirms that the
MetSyn is associated with increased cardiovascular risk, even in subjects over 70 years
of age. See page 1595. See figure.
(continued) A-48Heart Failure
The Quality Factor: A New End Point for Clinical Trials
Many clinical trials in cardiology are derided for their lack of “hard” clinicaloutcomes. These events, such as confirmed myocardial infarction or death, are
sometimes preferred because they are neither subjective nor the result of referral bias.
Although this is laudable, patients may not always prefer a treatment that results in
fewer deaths if it is associated with poor quality of life. In a substudy of the COMET
study, Cleland and colleagues calculated a “patient journey” score consisting of days
alive, out of hospital, and feeling well. Despite treatment with beta-blockers, death and
poor well being remained prominent and were of greater magnitude than hospitaliza-
tion. In an editorial related to a substudy from the COMET study, Stevenson and
Lewis describe why it may be important to ask study participants how they feel, rather
than just counting the hard end points at the end of the trial. See pages 1603 and
1612.
Cardiac Imaging
Validation of a Cardiac MRI Protocol for Detection of CAD
Cardiovascular magnetic resonance (CMR) has shown promise as a method fordetecting significant coronary atherosclerosis, but its adoption has been hindered
by both time-intensive interpretation protocols and a lack of standardization. Klem
and colleagues studied subjects with a moderate pretest probability for coronary artery
disease (CAD) who were referred for angiography. Before angiography, the subjects
underwent a comprehensive CMR study, including cine-CMR to assess wall motion,
rest and adenosine vasodilator perfusion images, and finally delayed-enhancement
imaging that visualizes areas of prior infarction. The scans were interpreted with a visual
grading score using 17-segment cardiac models, except the apex was excluded. The
combined protocol had sensitivity, specificity, and accuracy each over 85%. This CMR
protocol shows great promise for the detection of significant CAD and highlights how
the different modalities of CMR can be complementary to each other. See page
1630.
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Cardiac Imaging
Multidetector CT Angiography for Plaque Morphology
Although intravascular ultrasound (IVUS) can stratify atherosclerotic lesions asstable or potentially unstable, it requires invasive angiography limiting its wide-
spread use. Multidetector computed tomography (MDCT) may be able to not only
quantify stenosis, but also to delineate the composition of the obstruction and the
presence of coronary remodeling. Hoffman and colleagues performed MDCT in 37
patients with varying presentations of coronary atherosclerosis and correlated these
findings with coronary angiography. For approximately two-thirds of the lesions, they
were able to quantify the percent stenosis, the plaque area, and the area of the external
elastic membrane in a manner analogous to IVUS. They were also able to calculate the
percentage of the plaque that was calcified and, with some overlap, segregate lesions
into stable versus unstable. As the resolution of MDCT improves, so will the ability to
characterize lesions as stable or potentially unstable. See page 1655. See figure.
